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The United States Renal Data System (USRDS) was 
initiated in 1988. During the past 10 years it has grown 
to a remarkably complete and validated data system that 
has become the model and envy for national or regional 
end-stage renal disease (ESRD) registries. 
The National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK), in cooperation with the 
Health Care Financing Administration (HCFA), estab- 
lished the six goals of the USRDS for the current five- 
year contract. The first five deal with research and re- 








Design and implement a consolidated renal disease 
data system that will provide the biostatistical, data 
management, and analytical expertise necessary to 
characterize the total renal patient population and to 
describe the distribution of patients by sociodemo- 
graphic variables across treatment modalities. 
Report on the incidence, prevalence, mortality rates, 
and trends over time of renal disease by primary di- 
agnosis, treatment modality, and other sociodemo- 
graphic variables. 
Develop and analyze aggregate data on the effect of 
various modalities of treatment by disease and patient 
group categories. These data will be used to analyze 
the prevention and progression of renal disease with 
special emphasis on morbidity and mortality. 
Identify problems and opportunities for more focused 
special studies of renal research issues currently not 
addressed by the consolidated data system. 
Conduct cost effectiveness and other economic stud- 
ies pertaining to biomedical and epidemiologic as- 
pects of ESRD. 
Support investigator-initiated research by making 
data from the database widely available in convenient 
formats to the biomedical and economic research 
communities. 
This brief review focuses on the sixth goal for the 
purpose we describe here a) the data sources available to 
the USRDS and through the USRDS for others, b) more 
detailed data collections for USRDS special studies on 
random samples of patients that are also available to 
researchers, c) examples of the utility of data for answer- 
ing clinically relevant questions including issues of ap- 
propriate study design and interpretation of results, and 
d) access to USRDS data for clinicians and researchers. 
Data Sources for the USRDS 
The HCFA provides most of the existing data in the 
USRDS database. In addition to all the data from its 
ESRD Program Management and Medical Information 
System and the Annual Facility Survey, HCFA provides 
data on transplant follow-up and all Medicare-covered 
services derived from Medicare paid claims. These 
HCFA-supplied data are the core of the USRDS data- 
base. 
Since July 1990, selected data on non-Medicare pa- 
tients treated by the U.S. Department of Veterans Affairs 
(DVA) facilities have also been incorporated into the 
USRDS database. In July 1994, HCFA and the Health 
Resources Services Administration (HRSA) consoli- 
dated transplant data into a single collection, the United 
Network for Organ Sharing (UNOS), under its contract 
with HRSA. The expanded transplant data are shared 
among HRSA, HCFA, and the National Institutes of 
Health (NIH) and thus are available to the USRDS. The 
HRSA-collected transplant data include non-Medicare as 
well as Medicare patients. 
In addition, HCFA helps the USRDS with special 
studies. Most of the new, primary data for special studies 
are collected through the 18 ESRD networks, which are 
funded by HCFA under separate contracts. Data from the 
special studies are fully integrated into the USRDS da- 
purpose of assisting clinicians and researchers to en- 
hance their use of the USRDS data. In pursuit of this 
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tabase. Data collection began in March 1995 for an im- 
Portant new USRDS special study, the Dialysis Morbid- 
ity and Mortality Study (DMMS). This special study was 
drawn from all dialysis units in the United States and 
Obtained data On Over 203000 patients. 
Data in the USRDS database collected by HCFA’s 
ESRD networks, federal insurance carriers, and fiscal 
intermediaries are supplemented by data from the Social 
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Security Administration, the U.S. Bureau of the Census, 
local and national ESRD provider databases, and inter- 
national ESRD registries. 
USRDS Special Studies 
The USRDS has carried out a number of special stud- 
ies, most of which have been based on national random 
samples. Special study topics are approved by NIDDK, 
with recommendations from HCFA, the USRDS Scien- 
tific Advisory Committees, the ESRD networks, and the 
renal community. For each study, design and sampling 
plans were developed, samples were selected, and data 
collection forms and instructions were drafted, tested, 
finalized, and implemented with assistance from the net- 
works. These studies have resulted in standard analysis 
files (SAFs) as described below. The data collection 
forms used for several of the special studies can be found 
in the appendix of the USRDS Annual Data Report (1). 
Examples of USRDS special studies include the Case 
Mix Severity Study, CAPD and Peritonitis Study, Pedi- 
atric Growth and Development Study, Case Mix Ad- 
equacy Study, and most recently the DMMS. The latter 
study was performed in four waves of four mutually 
exclusive random samples of dialysis units. Thus virtu- 
ally each dialysis unit was included in only one data 
collection over a five-year period. To further reduce the 
burden only reasonably small random samples of pa- 
tients were chosen in each facility. The DMMS included 
numerous research topics such as dialyzer reuse, dialysis 
dose, dialyzer membrane, pre-ESRD care, nutrition, re- 
habilitation, treatment modality choice (selection), co- 
morbidites, peritoneal dialysis versus hemodialysis out- 
comes, vascular access, anemia therapy, laboratory data, 
and medications. Data from the first wave of the DMMS 
are already available to researchers through an SAF as 
described below. Much of the most interesting USRDS 
research comes from these special study data collections. 
Research Examples with Emphasis on 
Interpretation of Observational Results 
An almost endless list of examples could be provided, 
but we will limit this discussion to only a few examples. 
For additional examples readers are referred to the text of 
the USRDS 1997 Annual Data Report (1) and the list of 
USRDS publications that appears in the appendix at the 
end of the reference tables. Alternatively, this informa- 
tion can be found at the USRDS Web site at http:// 
www.med.umich.edu/usrds. 
Growth in incidence of treated ESRD. The number of 
patients starting ESRD therapy has been growing expo- 
nentially in the United States and in other countries (2), 
with a greater growth for elderly and diabetic patients. 
This greater growth has been attributed to increasing 
acceptance of older and sicker patients to ESRD therapy, 
that is, patients who previously had not been treated for 
their chronic uremia. However, even for younger adults, 
the USRDS has documented a similar exponential 
growth, albeit at a slower rate. An explanation for this 
observation may be that patients who used to die of 
conditions such as cardiovascular complications of dia- 
betes now live longer to reach the end stage of their renal 
complications. This competing risk may even explain 
some of the racial differences in incidence for younger 
age groups ( 3 ) .  Another explanation suggests that there 
may be more kidney disease in recent years through the 
growing prevalence of diabetes and the growing use of 
nonsteroidal anti-inflammatory drugs. 
The incidence rates for treated ESRD are closely 
watched by many in the renal community and the 
USRDS has been reporting the ESRD incidence counts 
and adjusted rates for the last nine years. In the last few 
years there have been some changes in reporting to 
HCFA, which made analyses of trends more difficult. 
The most recent USRDS analyses suggest that the counts 
for 1996 were lower than expected based on the trend 
line. Statistical analyses indicate that the 1996 counts 
were barely within the 95% confidence interval (thus not 
statistically different from the trend line at the 0.05 level) 
for the projected counts according to trends over the 
preceding years. Figure 1 shows the actual annual counts 
of newly treated ESRD incidence and the prediction for 
1996. Counts observed in the next few years will shed 
more light on these trends and will determine if this 
newest nonsignificant slowing in the growth of new 
ESRD patients will be confirmed. In the meantime, fur- 
ther evaluation of subgroups and statistical analyses may 
be used to differentiate random variation from changes in 
trends. 
DiaIyzer membrane use arid mortaliQ. Based on vari- 
ous observations it was hypothesized that mortality risk 
among hemodialysis patients varied by the type of mem- 
brane used. Dialyzer membranes can be categorized into 
three groups: unmodified cellulose, modified cellulose, 
and synthetic membranes. An evaluation of mortality 
risk was possible in a USRDS special study, which col- 
lected data on case mix, including comorbid conditions 
and delivered dialysis dose. The latter had to be restricted 
to patients who had been on ESRD therapy for more than 
one year to minimize the role of residual renal function. 
It was found to be an important factor since the average 
dose of dialysis (KtN) varied by the type of membrane. 
A Cox proportional hazards analysis of days to death or 
censor among hemodialysis patients showed that the risk 
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FIG. 1. Incident counts of newly treated ESRD by year with projec- 
tion to 1996 and actual count for 1996. The 95% confidence band 
indicates the range projected for 1996 according to counts from pre- 
vious years. 
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of death was significantly lower in patients treated with 
modified cellulose and synthetic membranes compared 
to unmodified cellulose membranes, all other measured 
patient factors being equal through statistical adjustment 
(4). Since membrane use varied by region, an additional 
analysis also adjusted for region covariables. Since the 
results remained virtually unchanged, the observed dif- 
ferences in outcome were independent of region, dialysis 
dose, or comorbid conditions. 
The interpretation of these statistically significant 
findings, however, included several possible mecha- 
nisms: a) greater biocompatibility; b) higher flux and 
thus greater clearance of middle molecules; c) require- 
ment of an ultrafiltration control device, which may al- 
low better attainment of dry weight; d) prescription of 
more expensive dialyzers by medical teams that provide 
care that is superior in other respects (“center effect”); 
and e) other unexamined factors. These possible mecha- 
nisms can be explored through additional observational 
research at the USRDS and through prospective trials. 
Despite not understanding the reasons, there is little 
doubt (p < 0.05) that patients treated in dialysis units that 
use different membranes actually had different out- 
comes. This investigation, then, helps focus future re- 
search and likely leads to better outcomes for hemodi- 
alysis patients. 
Comparative survival by diulytic treatment modality. 
Patients treated with hemodialysis (HD) can be com- 
pared to those treated with peritoneal dialysis (PD). 
Since PD patients in the US are on average six years 
younger than HD patients, it is clear that any comparison 
needs to take such differences into account. Additionally, 
differences in comorbid status beyond those explained 
by age do exist and reflect in part patient selection. The 
findings of these comparisons have shown no differences 
in outcomes for incident patient groups except for those 
with diabetic ESRD and among those only over 58 years 
of age (5) .  Among prevalent patients (treated with dialy- 
sis for various lengths of time), differences favoring HD 
appeared larger and emphasized differences in older and 
diabetic subgroups (6). The main point here is again the 
issue of careful interpretation of the statistically signifi- 
cant results. As shown in Figure 2, there are many po- 
tential factors that may contribute to these statistically 
significant observations (7). To mention only one: Com- 
pliance with PD may be poorer than with HD, and results 
among fully compliant HD and PD patients may give 
results that are much closer. 
Noiiproportional huzards. The Cox proportional haz- 
ards model is used frequently, but one needs to consider 
+ 
whether it is appropriate for the specific study. An ex- 
ample for nonproportionality is the comparison of dialy- 
sis with transplant patient mortality risk. Since transplan- 
tation adds a mortality risk due to surgery and the im- 
mediate postoperative course, standard Cox analysis 
restricted to the first few months after transplantation 
would likely show worse survival for transplant recipi- 
ents than for dialysis patients, while a long term follow- 
up would come to the opposite conclusion. This has been 
documented by analysis with the nonproportional Cox 
model that allows the relative mortality risk to vary with 
time. The risk was more than twofold higher during the 
first week post transplantation and subsequently mark- 
edly lower than for a dialysis group that had been on the 
transplant waiting list for the same duration (8, 9). There 
are potential fallacies with the Cox model (10); however, 
we observe that most errors occur in the design and 
planning of studies. 
Overall, to avoid erroneous or biased results, great 
caution has to be employed in the design of observational 
studies and in the use of appropriate adjustments. The 
second and third examples show that observational re- 
search has the limitation that it is difficult to ascribe a 
clear mechanism to the observations. However, there are 
numerous advantages to epidemiologic research based 
on USRDS data, including a) the description of national 
data and practices, b) the observation of outcomes based 
on the actual practice rather than the practice at research 
centers, c) the large volume of studies that can be per- 
formed in one year, d) the adjustment for numerous co- 
morbid and other factors in special study data collec- 
tions, and e) the relatively low cost, when compared to 
randomized controlled studies that can answer only few 
questions, usually at very great cost. 
Access to USRDS Microlevel Data and 
Other Statistics 
Goal 6 of the USRDS is to support investigator- 
initiated research by making data from the database 
widely available in convenient formats to the biomedical 
and economic research communities. One important 
means of making data available is through timely re- 
sponses to data requests made by researchers, practitio- 
ners, and other members of the renal community. 
As shown in Figure 3, the number of requests for 
information (‘ ‘2-hr data requests’ ’ ) has steadily increased 
over the years. During 1996 an average of one to two 
requests were filled per working day. Several requests 
Case Mix Treatment 
Outcomes Using the Cox Model 
Modality FIG. 2. Potential contributing factors for ob- 
served results in comparisons between peritone- 
al and hernodialysis patients. (From Ref. 7. used 
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FIG. 3. Number of data requests processed by the USRDS Coordi- 
nating Center by year, 1988-97. 
were filled regarding specific analysis files and several 
have led to scientific publications. Requests for statistics 
not available in the Annual Data Reports but that would 
require 2 hr or less of computer programmer/analyst time 
can be provided by the Coordinating Center, usually 
within one week of the request. Requests that require 
more than 2 hr of computer programmer/analyst time 
will be undertaken only upon written approval by the 
NIDDK project officer. Many of these more complex data 
requests can be met at low cost by obtaining USRDS 
SAFs or custom data files. Both of these files contain 
patient-level data. 
The USRDS has been sharing research data with other 
researchers for many years with the approval from the 
NIH/NIDDK project officer. Figure 4 shows the number 
as well as the size of requests for data files for research- 
ers outside of the USRDS that were filled from 1992 to 
November 1997, including pending requests. The figure 
shows the number of CD-ROMs provided to researchers 
by calendar year. Note that over 600 high-density floppy 
disks fit on one CD. Thus, there has been a clear increase 
in both the number of researchers and in the amount of 
information released for research during the recent years. 
The SAF make the USRDS database available to re- 
searchers in an easy-to-use and well-documented format. 
This approach allowed a major reduction in the produc- 
tion costs and thus a cost saving for researchers. These 
analysis files have patient-specific information, although 
patient identifiers and facility identifiers are encrypted. 
The SAFs are governed by the USRDS Policy on Data 
Release for Investigator-Initiated Research, and they re- 
quire that the research investigator’s proposal be ap- 
proved by NIDDK and that the researcher sign the 
USRDS Agreement for Release of Data, which means 
the researcher agrees to observe the prescribed restric- 
tions. These documents and further discussion of the 
SAFs can be found in the USRDS Annual Data Report. 
There has also been a marked growth in the amount of 
data provided. All requests except custom requests in- 
clude the core SAF CD. This CD includes basic patient 
data, each patient’s treatment history, full transplant and 
transplant follow-up data, and all data from the USRDS 
special studies. The hospitalization CD includes data 
about hospital inpatient stays except for payment data 
items. This file is too large to be included on the core 
CD. Historically about 40% of researchers have re- 
quested this file in addition to the core CD. The Medicare 
payment SAFs are used by only about 20% of the re- 
searchers, but these files account for 70% of the CDs 
provided. A full set of Medicare payment files requires 
36 CDs. 
CD-ROM technology has been crucial to the growth in 
the use and usability of the USRDS SAFs. Half of the 
researchers obtaining patient-level microlevel data files 
have needed only one CD to carry out their research. The 
full Medicare payment data would require 120 nine-track 
magnetic tapes instead of 36 CDs. Providing this volume 
of data on tape would not be practical. 
A wide variety of research topics have been addressed 
by researchers outside the USRDS using the USRDS 
SAFs. The reference tables in the annual data reports also 
are used extensively. In fact about half of recent Ameri- 
can Society of Nephrology abstracts, which were based 
Researcher Requests for USRDS Patient Level 
Data Files, and CD’s Supplied, 1992-1997 
1992 1993 1994 1995 1996 1997 1992 1993 1994 1995 1996 1997 
FIG. 4. Researcher requests for USRDS pa- 
tient-level data files and number of CDs supplied 
by year, 1992-97. Prior to early 1996, the num- 
bers indicate the files supplied on nine-track 
magnetic tape. For 1997, the projected total re- 
quests CDs are shown. 
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on USRDS data, used data from the annual data report 
reference tables rather than the SAFs. 
Conclusion 
The USRDS provides a wealth of information for cli- 
nicians and researchers. Specifically, it serves clinicians 
through analyses of a) national trends in number of 
treated patients, treatment, and outcome, b) patient care 
issues such as vascular access, patient compliance. iron 
therapy, and dose of dialysis, c) patient issues such as 
quality of life and access to care, d) facility-specific out- 
comes such as standardized mortality, hospitalization, 
and transplantation with national and regional standards. 
Additionally, the USRDS is a resource for inquiries and 
serves as a national reference. The USRDS also serves 
the researcher by making data and analysis files available 
a) through the World Wide Web (site noted above), b) 
through low-cost SAFs for special studies, and c) 
through tailored research files. Although many observa- 
tional studies using USRDS data provide useful infor- 
mation, there has to be vigilance and experience to avoid 
potential biases. Some of the USRDS studies have led to 
new questions and hypotheses that need to be answered 
by more detailed prospective trials. Members of the 
USRDS Coordinating Center are available for research 
questions and advice. Thus the USRDS serves numerous 
needs and has helped to improve patient care and to 
provide large research data sets to numerous research 
teams. It is our hope that this service to the clinical and 
scientific renal community will continue in the future. 
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Note added in proof 
The estimates in Figure 1 likely represent undercounts 
for 1996. More recent estimates (Jan. 1998) suggest that 
counts for 1996 are closer to the projected line. 
